Carbon Reduction Plan

Supplier name: Abbott Medical UK Ltd

Publication date: 30 June 2024

Overview

The UK (United Kingdom) Government amended the Climate Change Act 2008 in 2019 by introducing a target of at least a 100% reduction in the net UK carbon account (i.e. reduction of greenhouse gas emissions compared to 1990 levels) by 2050. This is otherwise known as the 'Net Zero' Target.

Action Note PPN 06/21, "Procurement Policy Note – Taking Account of Carbon Reduction Plans in the procurement of major government contracts," sets out how to take account of suppliers' Net Zero Carbon Reduction Plans in the procurement of major government contracts.

This plan outlines Abbott Medical UK Ltd.'s compliance with Action Note PPN 06/21 and carbon reduction performance in 2023.

Commitment to achieving Net Zero

Abbott Medical UK Ltd is committed to achieving Net Zero emissions by 2050. Abbott Medical UK Ltd. is a UK subsidiary of the ultimate parent Abbott Laboratories.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

Baseline Year: 2020

Additional Details relating to the Baseline Emissions calculations.

Our emissions data is reported in line with the GHGP Corporate Accounting and Reporting Standard under the 'Operational Control' approach. Scope 2 emissions are calculated using the GHGP market-based methodology. Per the GHGP, where market-based information is not available, location-based results have been used as proxy. Scope 3 emissions are calculated

primarily using a spend based approach and in line with the GHGP Corporate Accounting and Corporate Value Chain (Scope 3) Accounting and Reporting Standard (inflation has not been factored into the spend based calculation). The following categories are reported as Scope 3 emissions:

- Category 4: Upstream transportation and distribution
- Category 5: Waste generated in operations
- Category 6: Business travel
- Category 7: Employee commuting
- Category 9: Downstream transportation and distribution

2020 has been selected as our baseline. No emissions data was published prior to this in the UK.

Baseline year emissions: 2020	
EMISSIONS	TOTAL (tCO ₂ e)
Scope 1	226
Scope 2	37
Scope 3 (Included Sources)	2,269
Total Emissions	2,532


Current Emissions Reporting

Reporting Year: 2023	
EMISSIONS	TOTAL (tCO2e)
Scope 1	268
Scope 2	29
Scope 3 (Included Sources)	3,410

Emissions reduction targets

Abbott Medical UK Ltd.'s emissions targets align to Abbott's global strategy to protect a healthy environment as set out in our 2030 Sustainability Plan, and continue our progress to achieving Net Zero in the UK by 2050. Between 2020 and 2023, business growth for Abbott Medical UK Ltd., and the associated increase in activities, has led to a rise in greenhouse gas emissions. Initiatives to reduce carbon emissions are expected to offset the long-term effects of company growth. To see Abbott's global carbon reduction goals and progress, you can access our latest <u>Global Sustainability Report</u>. The following are our initial near-term carbon reduction targets, which are driven by the initiatives set out in the following section.

We project that carbon emissions will decrease to 2,000 tCO₂e by 2030. This is a reduction of 21%.



^{* 2022} emissions restated due to improved data collection process.

Carbon Reduction Projects

Completed Carbon Reduction Initiatives

The following environmental management measures and projects have been completed or implemented within Abbott Medical Ltd. since the 2020 baseline.

- Continued the transition to an electric vehicle fleet
- Removed fully diesel and petrol vehicles from the fleet choice list
- Introduced a requirement for all drivers to attend a training course on electrical vehicle technology
- Carbon reduction educational awareness
- Completed carbon reduction opportunity assessment
- Developed a detailed roadmap to reach Net Zero Scope 1 and 2 emissions in the UK by 2050.

In the future we hope to implement further measures such as:

- Further electrification of company vehicles
- Additional LED lighting upgrades
- Include net zero considerations (green heating and electricity) in office lease renewals and office relocations
- Consider energy efficiency as part of the evaluation of future building upgrades
- Further quantification and understanding of value chain environmental impacts

- Engaging the supply chain to manage and reduce our Scope 3 carbon emissions
- Continued educational awareness and training.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors on 29 June 2024.

Signed on behalf of Abbott Medical UK Ltd by:

Ross Campbell, Director

Date: 20 June 2024

² https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting

¹ <u>https://ghgprotocol.org/corporate-standard</u>

³ <u>https://ghgprotocol.org/standards/scope-3-standard</u>